Takeda

About

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company in Japan.

Osaka,Osaka,Japan
10001 - max
http://www.takeda.com

Highlights

Details

Last Funding Type: Grant
Last Funding Money Raised: $19.80M
Industries: Biotechnology,Health Care,Health Diagnostics,Medical,Pharmaceutical
Founded date: Jun 12, 1781
Number Of Employee: 10001 - max
Operating Status: Active
Stock Symbol: tyo:4502
Legal Name: Takeda Pharmaceutical Company Limited
Also Known As: TAP Pharmaceuticals,武田薬品工業
Investor Type: Venture Capital

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company in Japan.

The company markets its original products, such as the anti-prostatic cancer agent leuprolide acetate (marketed as Lupron Depot, Enantone, Prostap, and Leuplin), the anti-peptic ulcer agent lansoprazole (marketed as Prevacid, Ogast, Takepron, and other names), the anti-hypertensive agent candesartan cilexetil (marketed as Blopress, Kenzen, and Amias), and the anti-diabetic agent pioglitazone hydrochloride (marketed as Actos). Segments The company operates its business in two categories, Pharmaceutical business and Other businesses. The Pharmaceutical business represents the ethical drug business and healthcare business.

Other businesses include business activities involving the production and marketing of a range of products, including vitamin bulks, test reagents & clinical diagnostics, photographic chemicals, and inorganic chemicals.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

3

$57.80M

Takeda has raised a total of $57.80M in funding over 2 rounds. Their latest funding was raised on Sep 1, 2016 from a Grant round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Sep 1, 2016	Grant	$19.80M	—	—	—	Detail
May 8, 2016	Grant	$38M	1	—	—	Detail
May 14, 1999	IPO	—	—	—	—	Detail

Investments

Number of Investments

Number of Lead Investments

43

13

Takeda has made 43 investments. Their most recent investment was on Apr 19, 2022, when Hedge raised $3.70M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
Apr 19, 2022 Hedge	Seed	$3.70M	Blockchain	—
Dec 21, 2021 Ambys Medicines	Series A	$47M	Biotechnology	—
Oct 27, 2021 Cardurion Pharmaceuticals	Series B	$300M	Biotechnology	—
Nov 13, 2020 Bridge Medicines	Series Unknown	$10M	Pharmaceutical	—
Oct 6, 2020 xFOREST Therapeutics	Seed	—	Biotechnology	Yes

Investors

Number of Lead Investors

Number of Investors

—

1

Takeda is funded by 1 investors. Bill & Melinda Gates Foundation are the most recent investors.

Investor Name	Lead Investor	Funding Round
Bill & Melinda Gates Foundation	—	Grant

Employee Profiles

Number of Employee Profiles

50

Takeda has 50 current employee profiles, including Employee Andrea Pecci

Employee

Executive

Executive

Executive

Executive

Exits

Takeda has had 10 exits. Takeda most notable exits include Maverick Therapeutics , Avidity Biosciences

Date	Company Name	Exit Type	Industry
Mar 9, 2021	Maverick Therapeutics	M&A	Biotechnology	Detail
Jun 11, 2020	Avidity Biosciences	IPO	Biotechnology	Detail
Feb 26, 2020	PvP Biologics	M&A	Biotechnology	Detail
Jun 28, 2017	Mersana Therapeutics	IPO	Biotechnology	Detail
Mar 17, 2017	Molecular Templates	IPO	Biotechnology	Detail

Acquisition

Takeda has acquired 15 organizations. Their most recent acquisition was Syrrx on Feb 7, 2005. They acquired Syrrx for $270M.

Date Company Name	Industry	Acquisition Type	Price
Feb 7, 2005 Syrrx	Biotechnology	acquisition	$ 270M	Detail
Feb 1, 2008 Millennium Pharmaceuticals	Biotechnology	acquisition	$ 8.68B	Detail
Feb 1, 2008 Takeda Bio Development Center	Biotechnology	—	—	Detail
Jun 24, 2009 IDM Pharma	Biotechnology	—	—	Detail
May 19, 2011 Nycomed Pharma	Health Care	acquisition	€ 9.60B	Detail